Tag Archives: Says

With pivot to less-rare diseases, Alexion needs a new sticker-price plan, CEO says

SAN FRANCISCO—In 2019, Alexion is looking to pivot from an ultrarare-disease company to a rare-disease company—and it knows its pricing strategy has to change. With its top-selling therapy, Soliris, the company is moving into new diseases that aren’t nearly as rare as its previous targets. The drug recently nabbed an approval in generalized myasthenia gravis and is looking… Read More »

Federal judge says HHS Secretary Alex Azar exceeded legal authority in setting 340B drug payment rates

A federal court has sided with the American Hospital Association and others in ruling that the Department of Health and Human Services unlawfully cut payment rates for certain outpatient drugs. HHS Secretary Alex Azar exceeded his legal authority in setting new reimbursement rates in the outpatient prospective payment system rule for 2018, United States District… Read More »

HIV treatment outcomes continue to get better, says large analysis

The efficacy of first-line antiretroviral therapy (ART) continues to improve, according to an analysis of outcomes in 78,000 people in 181 studies, published in AIDS by Professor Andrew Carr of St Vincent’s Hospital in Sydney and colleagues. Over three-quarters of people who started treatment between 2011 and 2015 were still on their first regimen and… Read More »